Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary

To the Editor: After the publication of our letter,1 we received inquiries regarding our study and patient population. We appreciate the interest in our work and would like to clarify our study, report updates, and propose potential explanations for our findings.

http://ift.tt/2raNd3e